SAFFRON: Ph3 Savolitinib plus Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib

被引：0
|
作者：
Lu, S. [1 ]
Xu, W. [2 ]
Telaranta-Keerie, A. [3 ]
Jia, N. [4 ]
Hartmaier, R. [5 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Lung Canc Ctr, Shanghai, Peoples R China
[2] AstraZeneca, Oncol Late Dev, Oncol R&D, New York, NY USA
[3] AstraZeneca, Precis Med & Biosamples, Oncol R&D, Cambridge, England
[4] AstraZeneca, Oncol Biometr, Boston, MA USA
[5] AstraZeneca, Translat Med, Oncol R&D, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Locally advanced/metastatic NSCLC; osimertinib; savolitinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-13
引用
收藏
页码：S468 / S469
页数：2
相关论文
共 50 条
  • [1] SAFFRON: Savolitinib plus Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
    Lindsay, Colin
    Xu, Wanning
    Telaranta-Keerie, Aino
    Jia, Nan
    Hartmaier, Ryan J.
    Lu, Shun
    [J]. LUNG CANCER, 2024, 190
  • [2] SAFFRON: Savolitinib plus Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
    Piotrowska, Zofia
    Xu, Wanning
    Telaranta-Keerie, Aino
    Jia, Nan
    Hartmaier, Ryan
    Lu, Shun
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E25 - E26
  • [3] MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib plus osimertinib in EGFRm NSCLC Post-Osimertinib
    Ahn, M-J.
    De Marinis, F.
    Bonanno, L.
    Cho, B. C.
    Kim, T. -M.
    Cheng, S.
    Novello, S.
    Proto, C.
    Kim, S. -W.
    Lee, J. S.
    Metro, G.
    Yang, J. C.
    Xu, W.
    Hartmaier, R.
    Telaranta-Keerie, A.
    Poole, L.
    Sequist, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S469 - S470
  • [4] Baseline and on-treatment plasma-based genomics as a predictor of outcome in SAVANNAH: Savolitinib plus osimertinib in EGFRm MET overexpressed/amplified NSCLC post-osimertinib
    Hartmaier, Ryan James
    Markovets, Aleksandra
    Xu, Wanning
    Baczynska, Agata
    Todd, Alexander
    Ahn, Myung-Ju
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [5] Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
    Tan, Daniel Shao-Weng
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Lye Mun
    Hayashi, Hidetoshi
    Nhung, Nguyen
    Chia, Puey Ling
    De Marinis, Filippo
    Le, Xiuning
    Karachaliou, Niki
    Brutlach, Sabine
    Adrian, Svenja
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study
    Hartmaier, Ryan
    Han, Ji-Youn
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Cantarini, Mireille
    Frewer, Paul
    Frigault, Melanie M.
    Oxnard, Geoffrey
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [7] Osimertinib plus Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
    Han, J.
    Sequist, L.
    Ahn, M.
    Cho, B. C.
    Yu, H.
    Kim, S.
    Yang, J. C.
    Lee, J. S.
    Su, W.
    Kowalski, D. M.
    Orlov, S.
    Cantarini, M.
    Ren, S.
    Frewer, P.
    Ou, X.
    Janne, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S227 - S228
  • [8] Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
    Yang, James Chih-Hsin
    Chen, Yuh-Min
    Batra, Ullas
    Do, Kien
    Sitthideatphaiboon, Piyada
    Danchaivijitr, Pongwut
    Lee, Kang-Yun
    Chindaprasirt, Jarin
    Yang, Cheng-Ta
    Chang, Gee-Chen
    Charoentum, Chaiyut
    Ungtrakul, Teerapat
    Moran, Juan Ignacio Hernandez
    Hartmaier, Ryan
    Haskins, Matthew
    Xu, Wanning
    Riess, Jonathan W.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [9] SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
    Ahn, M.
    Cantarini, M.
    Frewer, P.
    Hawkins, G.
    Peters, J.
    Howarth, P.
    Ahmed, G.
    Sahota, T.
    Hartmaier, R.
    Li-Sucholeiki, X.
    Oxnard, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S415 - S416
  • [10] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
12345